Literature DB >> 11186130

Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance.

C R Bhasker1, W McKinnon, A Stone, A C Lo, T Kubota, T Ishizaki, J O Miners.   

Abstract

UGT2B7 catalyses the glucuronidation of a diverse range of drugs, environmental chemicals and endogenous compounds. Hence, coding region polymorphisms of UGT2B7 are potentially of pharmacological, toxicological and physiological significance. Two variant UGT2B7 cDNAs encoding enzymes with either His or Tyr at residue 268 have been isolated. The variants, referred to as UGT2B7*1 and UGT2B7*2, respectively, arise from a C to T transversion at nucleotide 802 of the UGT2B7 coding region. Analysis of genomic DNA from 91 unrelated Caucasians and 84 unrelated Japanese demonstrated the presence of the variant alleles encoding UGT2B7*1 and UGT2B7*2 in both populations. However, while there was an approximately equal distribution of subjects homozygous for each allele in the Caucasian population, subjects homozygous for the UGT2B7*1 allele were over 10-fold more prevalent than UGT2B7*2 homozygotes in Japanese. The frequencies of the UGT2B7*1 and UGT2B7*2 alleles were 0.511 and 0.489, respectively, in Caucasians, and 0.732 and 0.268, respectively, in Japanese. The 95% confidence intervals for the two alleles did not overlap between Caucasians and Japanese. Rates of microsomal androsterone, menthol and morphine (3-position) glucuronidation were determined for genotyped livers from Caucasian donors. Statistically significant inter-genotypic differences were not apparent for any of the three substrates. Although the UGT2B7 polymorphism characterized here is probably not associated with altered enzyme activity, the results highlight the need to consider ethnic variability in assessing the consequences of UGT polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11186130     DOI: 10.1097/00008571-200011000-00002

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  48 in total

Review 1.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

Review 3.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

Review 4.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

5.  The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene.

Authors:  Patricia McGettigan; Lisa F Lincz; John Attia; Patrick McElduff; Linda Bissett; Roseanne Peel; Barrie Stokes; Stephen Hancock; Kim Henderson; Michael Seldon; David Henry
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

6.  CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects.

Authors:  Sze Wa Chan; Miao Hu; Sara Shun Wah Ko; Catherine Wing Yan Tam; Benny Siu Pong Fok; Ophelia Qi Ping Yin; Moses Sing Sum Chow; Brian Tomlinson
Journal:  Eur J Clin Pharmacol       Date:  2012-10-23       Impact factor: 2.953

7.  Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.

Authors:  Hideaki Kagaya; Kazuyuki Inoue; Masatomo Miura; Shigeru Satoh; Mitsuru Saito; Hitoshi Tada; Tomonori Habuchi; Toshio Suzuki
Journal:  Eur J Clin Pharmacol       Date:  2007-01-09       Impact factor: 2.953

Review 8.  The Pharmacogenetics of Tramadol.

Authors:  Dorte Lassen; Per Damkier; Kim Brøsen
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

9.  Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

Authors:  Shane J Cross; John H Rodman; Jane C Lindsey; Brian L Robbins; Charles H Rose; Geoffrey J Yuen; Lawrence J D'angelo
Journal:  J Acquir Immune Defic Syndr       Date:  2009-05-01       Impact factor: 3.731

10.  Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.

Authors:  Dong Gui Hu; Theresa E Hickey; Connie Irvine; Dhilushi Dodampege Wijayakumara; Lu Lu; Wayne D Tilley; Luke A Selth; Peter I Mackenzie
Journal:  Horm Cancer       Date:  2014-02-26       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.